HCM: חוב מצטבר של החברה HUTCHMED

Stable cash flow from Chinese sales and licenses ensures the resilience of HUTCHMED (HCM). The volume of borrowed funds illustrates the current debt load, where 0.08 determines the current value of the metric. HUTCHMED (HCM) is scaling the expansion of fruquintinib in the US and EU, while simultaneously developing global partnerships with pharma behemoths to conduct international clinical trials.

When assessing the resilience of HUTCHMED (China) Limited (HCM), investors must consider the cost of expansion into the US oncology sector amid pressure from global pharma behemoths. By analyzing the debt trend chart, we measure the total volume of borrowed funds, which determines the issuer's degree of financial dependence and the risk of overpaying on interest, directly impacting the company's free capital preservation.